Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keros Therapeutics, Inc.

14.57
+0.13000.90%
Post-market: 14.570.00000.00%19:54 EDT
Volume:366.75K
Turnover:5.36M
Market Cap:591.77M
PE:133.72
High:14.83
Open:14.44
Low:14.44
Close:14.44
Loading ...

Keros Therapeutics Inc -Plans on Advancing Ker-065 Into a Phase 2 Clinical Trial in Dmd, Subject to Positive Regulatory Interaction

THOMSON REUTERS
·
31 Mar

Keros Therapeutics Inc: Ker-065 Was Generally Well-Tolerated, With No Major Safety Signals Observed to Date

THOMSON REUTERS
·
31 Mar

Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet

Zacks
·
21 Mar

Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade

Zacks
·
05 Mar

Keros Therapeutics CEO to Speak at Major Conferences

TIPRANKS
·
01 Mar

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

GlobeNewswire
·
01 Mar

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Kura Oncology (KURA) and Silence Therapeutics (SLN)

TIPRANKS
·
28 Feb

Keros Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Oneview Healthcare Chess Depository Interests repr 1 (OtherONVVF) and Teladoc (TDOC)

TIPRANKS
·
27 Feb

TD Cowen Remains a Hold on Keros Therapeutics (KROS)

TIPRANKS
·
27 Feb

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
27 Feb

Keros Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Keros Therapeutics Q4 EPS $(1.14) Misses $(0.96) Estimate, Sales $3.04M Miss $15.42M Estimate

Benzinga
·
27 Feb

BRIEF-Keros Therapeutics Q4 EPS USD -1.14

Reuters
·
27 Feb

Keros Therapeutics Q4 EPS USD -1.14

THOMSON REUTERS
·
27 Feb

Keros Therapeutics Inc - Expects Cash Runway Into 2029

THOMSON REUTERS
·
27 Feb

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
27 Feb

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma

Business Wire
·
26 Feb

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma

Business Wire
·
06 Feb

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Business Wire
·
28 Jan